Updated efficacy and safety of lenvatinib (LEN) plus pembrolizumab (pembro) vs treatment of physician's choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): Study 309/KEYNOTE-775

ANNALS OF ONCOLOGY

ELSEVIER

1. Eisai Inc., Nutley, NJ, USA
2. Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA